Pfizer Invests $743M in Ingredient Plant Expansion

Pfizer has invested US $743 million to expand its automated active pharmaceutical ingredient manufacturing facility in Singapore.

The new state-of-the-art facility extension is located in Singapore's Tuas Biomedical park and spans 429,000 sq. ft. The facility will produce various small molecule APIs for Pfizer’s oncology, pain, and antibiotic medicines to markets across the world, according to BioSpectrum Asia Division.

Designed to facilitate lean material movement, reduce lead times, and fast process turnarounds, the facility began construction in 2020. In order to reduce energy usage and manage energy demand more effectively, systems and technologies are integrated while maintaining best practices in Good Manufacturing Practices (GMP). Additionally, the facility has the capacity to add processing suites, dry-end suites, dispensaries, warehouses, and ancillary equipment as needed.

“Pfizer’s latest investment in Tuas Biomedical Park reinforces Singapore's standing as a leading biomedical sciences hub and also demonstrates how global biopharmaceutical companies can tap on our talent and capabilities to manufacture therapies for the world. We look forward to deepening our longstanding partnership with Pfizer to create meaningful jobs and economic opportunities for Singapore," said Jacqueline Poh, managing director, Singapore Economic Development Board.

The expansion has significantly strengthened the commercial and manufacturing capabilities of Pfizer in Singapore. Pfizer is creating more than 250 new highly skilled jobs with the expansion of the API plant site. Pfizer has more than 30 sites across six continents.

“With the facility expansion, Pfizer continues to grow its resilient and innovative global supply network. We are expanding our manufacturing footprint and strengthening our ability to manufacture breakthrough medicines” said Mike McDermott, chief global supply officer and executive vice president of Pfizer.

Additionally, the facility has achieved Green Mark gold certification, an accreditation for environmental sustainability in Singapore. With these actions, Pfizer aims to achieve the Net-Zero standard by 2040 and contribute to a more sustainable future.